Onset of immunity:	3 weeks after vaccination
Duration of immunity:	6 months (demonstrated by challenge studies) after vaccination for BRSV and BVDV Type 1. Duration of immunity has not been established for bovine Pi3 virus.

Efficacy has not been demonstrated against BVDV Type 2 strains.

Dose to be administered and administration route

Reconstitute the vaccine by adding the liquid to the vial containing the lyophilized fraction.

When the lyophilised fraction and liquid fraction are filled in equally sized vials, inject the entire liquid fraction into the lyophilized fraction vial.

When the lyophilised fraction is filled in a smaller vial size than the liquid fraction, the reconstitution of the vaccine is carried out in 2 steps:

1. Inject 10ml of the liquid fraction on the lyophilised plug in the lyophilized fraction vial.

2. Shake well and extract the reconstituted lyophilised fraction from the lyophilized fraction vial and mix with the liquid fraction in the liquid fraction vial.

Shake well before use.

Administer one dose (4 ml) of the reconstituted vaccine by intramuscular route according to the following vaccination scheme:

First injection: from 12 weeks of age.

Second injection: 3 to 4 weeks later.

Animals should be preferably vaccinated at least 3 weeks before a period of stress or high infection risk like re-grouping or transport of animals, or the start of autumn season. If protection against BRSV and BVDV type 1 is required, then animals should be revaccinated after 6 months. The duration of immunity of the Pi3 component is not known.

Adverse reactions

Transient and mild hyperthermia which can last for 2 days and t a transient, minor local inflammation reaction of up to 0.5 cm which disappears within 15 days can occur very commonly after administration of the vaccine. Very rarely, the vaccine may cause hypersensitivity reactions. In case of anaphylactic reaction, symptomatic treatment should be provided.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).